摘要
目的观察和评价卡培他滨单药维持化疗治疗晚期转移性乳腺癌的临床疗效、生活质量改善和不良反应。方法 54例经病理学检查确诊的晚期转移性乳腺癌患者分为实验组30例,在以卡培他滨为主的两药联合化疗完成后,给予卡培他滨单药维持,剂量1 250 mg/m2,每天早、晚餐后30分钟口服,连服14天,21天为1周期,每2周期评价疗效,病灶进展则停药;对照组24例进行随访观察。结果实验组30例患者均可评价疗效,CR 0例,PR9例,SD 16例,PD 5例,有效率为30.0%,疾病控制率(CR+PR+SD)为83.3%(25/30),TTP、中位生存期及1年、2年生存率分别为6.1月、11.7月和56.7%、36.7%。对照组TTP、中位生存期及1年、2年生存率分别为5.4月、10.6月和54.1%、33.3%。实验组生活质量改善者占63.3%(19/30)。实验组常见的不良反应为手足综合征(60.0%)、皮肤色素沉着(46.7%)、腹泻(13.3%)、恶心、呕吐(13.3%)、口腔发炎(6.7%)、白细胞减少(20.0%)及血小板减少(10.0%),均能够耐受。结论卡培他滨单药维持化疗治疗晚期转移性乳腺癌,可延长患者生存时间,改善生活质量,不良反应轻,值得临床进一步研究。
Objective To investigate the clinical effectiveness and toxicity of chemotherapy with capecitabine-alone in the treatment for metastatic breast cancer patients, and to observe the improvement of quality of life. Methods Fifty-four metastatic breast cancer patients confirmed by histopathology and/or cytology were devided into therapy group and control group. When the two-drug regimen based on capecitabine were finished ,30 patients received maintenance chemotherapy with capecitabine-alone in therapy group. The patients received capecitabine 1 250 mg/m2 orally twice daily from day 1 to 14, repeated every three weeks. Each patient was treated at least two cycles, the efficacy was evaluated every two cycles. When the disease progressed, the treatment was discontinued. Twenty-four patients of control group were followed up. Results In therapy group, all patients were evaluable, the disease control rate was 83.3% with CR in 0,PR in 9,SD in 16 and PD in 5. The response rate was 30.0%. The median time to progression was 6.1 months and median overall survival time was 11.7 months, the 1-year, 2-year survival rates were 54.1% , 33.3%, the improvement of quality of life accounted for 63.3% （ 19/30 ）. Toxicities were hand-foot syndrome （60.0%）, skin pigmentation （46.7%）, diarrhea （ 13.3 % ） , nausea and vomiting （ 13.3 % ）, oral mucositis （6.7 % ） , leukopenia （20.0%）, thrombocytopenia （ 10.0% ）, all patients were able to tolerate. Conclusions Patients with metastatic breast cancer can benefit from the maintenance chemotherapy with capecitabine-alone. It can not only prolong survival time but also improve quality of life, and the toxicities are well tolerated. Further study is worth to do.
出处
《实用肿瘤杂志》
CAS
2013年第5期516-519,共4页
Journal of Practical Oncology
关键词
乳腺肿瘤
药物疗法
卡培他滨
治疗应用
肿瘤转移
生活质量
随访研究
breast neoplasms/drug therapy
capecitabine/therapeutic use
neoplasm metastasis
quality of life
follow-up studies
